_____________________________________________________________________________________________________ *Corresponding author; J. Adv. Med. Med. Res., vol. 35, no. 11, pp. 13-21, 2023 Journal of Advances in Medicine and Medical Research Volume 35, Issue 11, Page 13-21, 2023; Article no.JAMMR.98271 ISSN: 2456-8899 (Past name: British Journal of Medicine and Medical Research, Past ISSN: 2231-0614, NLM ID: 101570965) Research of Natural Killer Cell (CD56+, CD16+, CD3-) and It's Activating Ligand (CD 112) in Acute Myeloid Leukemia Marwa Abd Elstar Salama a* , Hossam Hodeib a , Atef Mohamed Taha b and Mohamed Kamal Zahrah a a Clinical Pathology Department, Faculty of Medicine, Tanta University, Tanta, Egypt. b Internal Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt. Authors’ contributions This work was carried out in collaboration among all authors. All authors read and approved the final manuscript. Article Information DOI: 10.9734/JAMMR/2023/v35i115023 Open Peer Review History: This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: https://www.sdiarticle5.com/review-history/98271 Received: 07/02/2023 Accepted: 10/04/2023 Published: 18/04/2023 ABSTRACT Background: Myeloid, erythroid, megakaryocytic, and monocytic cell lineage progenitors are all involved in the development of acute myeloid leukemia (AML), making AML a highly diverse collection of leukemias. This research was aimed to evaluate the impact of natural killer cell (CD56+, CD16+, CD3-) and its activating receptor ligand (CD 112) on AML and their clinicopathological significance. Methods: This prospective randomized research was carried out on 40 newly diagnosed AML, and 20 apparently healthy subjects age and sex matched to cases group. (Determination of natural killer cell and activating receptor ligand). Results: There was an evident decrease in percentage of NK cells in newly diagnosed AML cases. There was an evident increase in expression of CD112 in newly diagnosed AML cases. An evidently higher OS in cases with low NK cells expression with cutoff ≤15.5. Original Research Article